New bivalent PKC ligands linked by a carbon spacer: Enhancement in binding affinity

被引:27
作者
Sridhar, J
Wei, ZL
Nowak, I
Lewin, NE
Ayres, JA
Pearce, LV
Blumberg, PM
Kozikowski, AP
机构
[1] Georgetown Univ, Ctr Med, Dept Neurol, Drug Discovery Program, Washington, DC 20057 USA
[2] NIH, Cellular Carcinogenesis & Tumor Promot Lab, Bethesda, MD 20892 USA
关键词
D O I
10.1021/jm0302041
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein kinase C (PKC) is known to play an important role in many signal transduction pathways involved in hormone release, mitogenesis, and tumor promotion. In continuation of our efforts to find highly potent activators of PKC for possible use as Alzheimer's disease therapeutics, we designed and synthesized molecules containing two binding moieties (amides of benzolactams or esters of naphthylpyrrolidones) connected by a flexible spacer chain, which could theoretically bind to both the C1a and C1b activator binding domains of the catalytic region or to the C1 domains of two adjacent PKC molecules. The dimers 2a- g of benzolactam showed a 200-fold increase in affinity to PKCalpha and -delta as the spacer length increased from 4 to 20 carbon atoms. Replacement of the oligomethylene chain with an oligoethylene glycol unit (compounds 2h, 2i) showed a 4000- to 7000-fold decrease in affinity to PKCalpha. The dimers of naphthylpyrrolidones 4a-g did not show any marked improvement in binding affinities to PKC in comparison to the monomers synthesized earlier. The dimer of benzolactam. 2e did not show much selectivity for PKCalpha, -betaI, -delta, -epsilon, and -gamma. The high binding affinity of compounds 2d-g to PKCs gives us the impetus to design additional molecules that would retain this enhanced activity and would also show selectivity for the PKC isoforms.
引用
收藏
页码:4196 / 4204
页数:9
相关论文
共 41 条
[1]   STRUCTURAL REQUIREMENTS OF LYNGBYATOXIN-A FOR ACTIVATION AND DOWN-REGULATION OF PROTEIN-KINASE-C [J].
BASU, A ;
KOZIKOWSKI, AP ;
LAZO, JS .
BIOCHEMISTRY, 1992, 31 (15) :3824-3830
[2]   Comparison of the roles of the C1a and C1b domains of protein kinase C alpha in ligand induced translocation in NIH 3T3 cells [J].
Bögi, K ;
Lorenzo, PS ;
Acs, P ;
Szállási, Z ;
Wagner, GS ;
Blumberg, PM .
FEBS LETTERS, 1999, 456 (01) :27-30
[3]  
Bögi K, 1998, CANCER RES, V58, P1423
[4]   Drug design - Discovering high-affinity ligands for proteins [J].
Hajduk, PJ ;
Meadows, RP ;
Fesik, SW .
SCIENCE, 1997, 278 (5337) :497-&
[5]  
Hurley JH, 1997, PROTEIN SCI, V6, P477
[6]   Molecular basis for protein kinase C isozyme-selective binding: The synthesis, folding, and phorbol ester binding of the cysteine-rich domains of all protein kinase C isozymes [J].
Irie, K ;
Oie, K ;
Nakahara, A ;
Yanai, Y ;
Ohigashi, H ;
Wender, PA ;
Fukuda, H ;
Konishi, H ;
Kikkawa, U .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1998, 120 (36) :9159-9167
[7]   Comparison of chemical characteristics of the first and the second cysteine-rich domains of protein kinase C gamma [J].
Irie, K ;
Yanai, Y ;
Oie, K ;
Ishizawa, J ;
Nakagawa, Y ;
Ohigashi, H ;
Wender, PA ;
Kikkawa, U .
BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (08) :1725-1737
[8]   Establishment of a binding assay for protein kinase C isozymes using synthetic C1 peptides and development of new medicinal leads with protein kinase C isozyme and C1 domain selectivity [J].
Irie, K ;
Nakahara, A ;
Nakagawa, Y ;
Ohigashi, H ;
Shindo, M ;
Fukuda, H ;
Konishi, H ;
Kikkawa, U ;
Kashiwagi, K ;
Saito, N .
PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) :271-281
[9]   ON THE ATTRIBUTION AND ADDITIVITY OF BINDING-ENERGIES [J].
JENCKS, WP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (07) :4046-4050
[10]   RESIDUES IN THE 2ND CYSTEINE-RICH REGION OF PROTEIN-KINASE-C-DELTA RELEVANT TO PHORBOL ESTER BINDING AS REVEALED BY SITE-DIRECTED MUTAGENESIS [J].
KAZANIETZ, MG ;
WANG, S ;
MILNE, GWA ;
LEWIN, NE ;
LIU, HL ;
BLUMBERG, PM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (37) :21852-21859